Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial

202232 citationsJournal Articlegreen Open Access

Authors

Atsushi Tanaka · Saga University

Masataka Sata · Tokushima University Hospital

Yosuke Okada · University of Occupational and Environmental Health Japan

Hiroki Teragawa · Futaba (Japan)

Katsumi Eguchi · Saitama Red Cross Hospital

Michio Shimabukuro · Fukushima Medical University

Isao Taguchi

Abstract

Twenty-four months of ipragliflozin treatment did not affect carotid IMT status in patients with type 2 diabetes recruited in the PROTECT study, relative to the non-SGLT2 inhibitor-use standard care for type 2 diabetes.

Topics & Keywords

Diabetes Treatment and Management Cardiovascular Health and Disease Prevention Regulation of Appetite and Obesity

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal - Cardiovascular Pharmacotherapy

Volume 9, Issue 2, pp. 165-172

DOI: 10.1093/ehjcvp/pvac059

Field-Weighted Citation Impact: 4.47